Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$18.45 USD

18.45
7,100,133

+0.01 (0.05%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $18.45 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (49 out of 250)

Industry: Medical - Generic Drugs

Better trading starts here.

Zacks News

Allergan's Botox Gets FDA Nod for Forehead Line Treatment

Allergan (AGN) secures an FDA approval for Botox Cosmetic product for its third indication of forehead line development.

    Allergan (AGN) Pipeline & New Drugs to Counter Generic Woes

    Allergan's key drugs like Botox/Linzess and new drugs are supporting sales. However, Allergan faces generic threat for Namenda franchise and patent challenges for some other branded drugs.

      Teva Reintroduces Generic Depo-Provera Injection in U.S.

      Teva (TEVA) announced the reintroduction of the generic equivalent to Depo-Prover Contraceptive Injection 150 mg/mL in the United States.

        Impax Generic Division Progresses Well Amid Pricing Pressure

        Impax Laboratories' (IPXL) generic portfolio has progressed well so far this year. Moreover, approval of the generic versions of Vytorin and Concerta is a positive.

          Allergan Authorizes New $2B Share Buyback Plan, Stock Up

          Allergan plc (AZN) sanctions a new stock repurchase program. The company also reiterates its commitment toward annual hike of quarterly cash dividend.

            Teva/Nuvelution to Speed Up Development of Austedo in US

            Teva Pharma (TEVA) and Nuvelution inked a deal to accelerate the development of Austedo (deutetrabenazine) tablets for the treatment of tics associated with Tourette syndrome.

              Teva's Leukemia Drug sNDA Granted Priority Review by the FDA

              Teva Pharmaceutical's (TEVA) sNDA for label expansion of Trisenox as first-line treatment of acute promyelocytic leukemia has been accepted by the FDA under priority review.

                Company News For Sep 13, 2017

                Companies in the news are: TEVA,WDC,AMZN,LMNR

                  Teva's New CEO Brings No Relief: Generic Drugmakers to Dump

                  The New CEO appointment at Teva (TEVA has once again shifted focus to the Generic Drug industry, which is presently facing several challenges.

                    Company News For Sep 12, 2017

                    Companies in the news are: TEVA,BMY,EFX,FB

                      Cooper Companies Buys Teva's PARAGARD Intrauterine Platform

                      Cooper Companies (COO) latest development is expected to fortify its foothold in the contraceptive device market. Margins are likely to improve within one year of the deal closure.

                        Ryan McQueeney headshot

                        Why Did Teva Pharmaceuticals Stock Soar Today?

                        Shares of Teva Pharmaceuticals (TEVA) opened more than 15% higher on Monday after the struggling drugmaker picked H. Lundbeck (HLUYY) chief Kare Schultz to fill its long-vacant CEO role.

                          Teva Hires Kare Schultz as CEO: Is a Recovery in the Cards?

                          Teva Pharmaceutical (TEVA) announced the appointment of H. Lundbeck's Kare Schultz as President and Chief Executive Officer (CEO).

                            Amgen/AstraZeneca Asthma Candidate Tezepelumab Shows Promise

                            Amgen (AMGN) and AstraZeneca (AZN) announced promising data from a phase IIb study on tezepelumab, which reduced the rate of deterioration of asthma in patients with severe uncontrolled asthma.

                              Novartis' (NVS) MS Drug Gilenya Positive in Long-Term Study

                              Novartis AG (NVS) announced positive top-line results from the phase III study, PARADIGMS on MS Drug Gilenya for children and adolescents.

                                Teva Austedo Gets FDA Nod for Label Expansion in Dyskinesia

                                Teva Pharmaceutical (TEVA) announced that the FDA has approved the label expansion of Austedo to include tardive dyskinesia in adults. Shares are up since announcement.

                                  Impax Laboratories (IPXL) Q2 Earnings Beat, Revenues Up Y/Y

                                  Impax Laboratories (IPXL) reported positive second-quarter results with earnings and sales both beating estimates. The company has strengthened its generic portfolio with additional approvals during the quarter.

                                    Brian Bolan headshot

                                    SolarEdge (SEDG) and Teva (TEVA) are Blowouts!

                                    One stock is being blown off the books and one had a blow out earnings report.

                                      Ryan McQueeney headshot

                                      Teva Plunges to 10-Year Low, Credit Rating in Jeopardy

                                      Shares of Teva Pharmaceuticals (TEVA), a favorite for investors chasing large dividend yields, fell more than 4.4%--and hit a 10-year intraday low--on Wednesday.

                                        VIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y

                                        VIVUS reported dismal second-quarter results wherein its loss widened from the year-ago period on lower sales.

                                          Arpita Dutt headshot

                                          Generic Drug Stocks Take a Hit: Here's Why

                                          As generic drug pricing concerns loom large, Teva (TEVA) and other players in the generic market saw their shares tumble last week.

                                            Teva Q2 Earnings Lag, '17 View & Dividend Cut, Stock Slumps

                                            Teva Pharmaceutical Industries Limited's (TEVA) Q2 earnings and missed expectations. It also slashed its 2017 earnings and sales outlook and cut its dividend by 75%.

                                              Allergan (AGN) Q2 Earnings & Sales Top, Restasis Sales Down

                                              Allergan plc (AGN) beat estimates for both earnings and sales in Q2. The company raised its 2017 outlook. Shares were down slightly in pre-market trading.

                                                Teva (TEVA) Q2 Earnings and Sales Miss, Shares Down

                                                Teva Pharmaceutical (TEVA) second quarter earnings and revenue missed estimates. The company has also lowered its earnings and revenue guidance for 2017.

                                                  What's in Store for Arena (ARNA) this Earnings Season?

                                                  Although Belviq, the only approved product in Arena's (ARNA) portfolio, has an unimpressive performance so far, the company's efforts to improve the drug's performance might drive the stock in Q2.